Development of and access to products for neglected diseases.

ABSTRACT:

Introduction

Prior research on neglected disease drug development suggested inadequate funding was responsible for relatively few new approvals. In response, significantly more resources have been allocated towards development of drugs targeting neglected diseases. Our objective was to reassess drug development between 1975 and 1999, evaluate progress in neglected disease drug development since 2000, and explain how increased numbers of approvals are a necessary but insufficient condition to improving access.

Methods

To assess numbers of approvals targeting neglected diseases, we employed two distinct methodologies: First, to revisit numbers published in Trouiller et al. (2002) we used their method to count marketed new chemical entities (NCEs) between 1975 and 1999. Second,

SUBMITTER: Cohen J 

PROVIDER: S-EPMC2868904 | biostudies-literature | 2010 May

REPOSITORIES: biostudies-literature